Home / The Company / Publications

About Annoyouda


Founded in 2012, Annoyouda Gene Technology is a well-known enterprise in China's genome industry, a leading NIPT service provider in China, focusing on the industrialization of next-generation genomics technology in human health and life science research. application.

Since its inception, Annoyouda has been recognized as the first high-throughput sequencing clinical application pilot unit of the National High-Tech Enterprise and the National Health Planning Commission. The National Development and Reform Commission's first batch of genetic testing technology application demonstration center, Beijing Municipal Development and Reform Commission "precision medical and genetic Engineering Beijing Engineering Laboratory, Zhongguancun High-tech Enterprise, the first batch of Beijing Biomedical Industry Leap-forward Development Project (G20 Project) during the “13th Five-Year Plan” period, with post-doctoral scientific research workstations, selected as one of the top 30 most technologically advanced enterprises in China The top 50 most valuable investment companies in China.

Based on the core talent team at home and abroad, Annoyouda has its own leading genome sequencing and bioinformatics technology, and launched the leading desktop high-throughput sequencer NextSeq 550AR and the bio big data platform “Anno Cloud”. At present, it has excellent product system and brand effect in sequencing equipment and molecular diagnostic reagents, medical testing and research, scientific research services, gene big data and cloud platform services, forming a whole industrial chain covering the upstream, midstream and downstream of the business. The layout and powerful Bio-IT industrialization service capabilities have won high recognition from our partners.

About Annoyouda South Center


Zhejiang Annuo Youda Biotechnology Co., Ltd. was officially completed in July 2018. As the South Center of Annoyouda, it will rely on the core advantages of Annoyouda Beijing headquarters in the genetic sequencing industry chain, middle and downstream resources, to build a medical inspection center, genetic research institute, instrument reagent manufacturing center, genetic health center. The four core functional genetic technology ecosystems strive to become a new business card for Yiwu. Together with the headquarters of Annoyouda, we adhere to the concept of “enhancing the quality of life with technology and innovation” and jointly build medical and health care that integrates “big science, big manufacturing, big health, big service, big data and big resources”. An excellent company in the field.

After the completion of the Medical Testing Center, it will become one of the core testing bases in the field of reproductive health and cancer detection in the country, and the laboratory with the largest sample processing capacity in East China. The Gene Research Institute will have a world-class research team and become a leading international company. Sequencing Center and Large Data Processing Supercomputing Center, the world's only three-dimensional genomics research center, the world's leading single-cell multi-omics research center; Gene Health Center strives to become the most comprehensive genetic health industry in the nationwide detection technology and production platform Base, in the future will reach 150,000 years of test sample volume, thereby improving the level of residents' health management and disease prevention; in addition, the Gene Health Center will work with local medical regulatory authorities to promote standardized and industrialized genetic testing applications. The instrument reagent manufacturing center will form an upstream layout of the industrial chain and become a demonstration base for instrument and reagent manufacturing and operation management.

Annan Youda South Center will rely on the unique location advantages, and Nanjing Annuo Youda, Guangzhou Annuo Youda and other subsidiaries in line with the North Center - Beijing headquarters, the formation of a "one South and a North double" nationwide Center, to build a leading eco-type enterprise in the genome industry, adhering to the concept of using technology and innovation to enhance the quality of life, to create a whole industry chain layout from upstream instruments, reagent manufacturing to midstream big data services and downstream medical, health and technology services applications. .


About Nanjing Annuo Youda Gene Technology Co., Ltd.

Nanjing Anuoyouda Gene Technology Co., Ltd. (hereinafter referred to as Nanjing Anuo) was established by Annoyouda Gene Technology (Beijing) Co., Ltd. (hereinafter referred to as Annoyouda) and Nanjing Yangzi State-owned Investment Group. Strategic cooperation in the production of the era big data and the Chinese human genome data mining.

As one of the first invited companies, Nanjing Anno has officially entered the National Health Medical Big Data Application Center and started the Nanjing Experimental Production Center. At present, Nanjing Experimental Production Center has the latest sequencing platforms such as NovaSeq, PacBio sequel and HiSeq X Ten. Relying on the platform advantage of the experimental production center and the technological research and development advantages of Annoyouda in the field of gene sequencing, Nanjing Anuo will provide more quality services for the majority of scientific research workers, and actively promote the transformation and application of genetic big data in human medical health. .

Nanjing Anuo is a key step for Annoyouda to develop a strategic strategy for the domestic market. Annoyouda will give full play to the advantages of regional resources, focus on key areas of development, optimize the industrial structure, and create more value for the gene big data industry with innovation, efficiency and win-win.

Primary founder

Xia Zuoquan Chairman Angel Investor

Graduated from Beijing University of Science and Technology and Peking University Guanghua School of Management, Annoyouda Angel investor, BYD co-founder, current chairman of Annoyouda, chairman of Shenzhen Zhengxuan Investment, director of BYD, is a successful entrepreneur in China and One of the investors has extensive experience in corporate governance and risk control.

Li Dawei CEO Co-founder

Beijing Economic and Technological Development Zone “New Innovation Project · Qilin” talents, with nearly 20 years of research and development and management experience in the field of gene sequencing, is the first batch of domestic construction of sequencing platforms, new technology research and development, production and operation, financial management, supply chain system Build and manage comprehensive talents.

Chen Reconstruction President Co-Founder

Researcher, special expert in Beijing, visiting professor at Huazhong Agricultural University. Biotechnology and computer academic background, obtained double doctoral degrees from Paris 11 University and Sun Yat-sen University, completed postdoctoral research at the Curie Institute in France. He is currently the director of the Beijing Precision Medical and Genetic Engineering Laboratory and the vice chairman of the Chinese Research Hospitals Association for the Precision Diagnosis of Hematology. He has been rated as "Beijing Haiju Engineering Talents", "Zhongguancun Ten Seas to Start a New Star", "Beijing Economic and Technological Development Zone Leading Talents", "Beijing Economic and Technological Development Zone Overseas High-level Talents", the 8th Beijing Excellent Young talents, "2015-2016 Beijing Excellent Entrepreneur", 2017 "Capital Labor Medal", "Thirty-first Beijing Youth May Fourth Medal", "China Youth Entrepreneurship Award" winner, in Nature, Science More than 19 academic papers have been published in international journals such as Elife, Developmental Cell, Genome Biology, and Bioinformatics. (PubMed1 PubMed2)

Academic article published:

  Nature Structure & Molecular Biology. 2017 Jan 30. doi: 10.1038/nsmb.3365.

  Nature. 2016 July 18. doi: 10.1038.

Oncotarget. 2016 Jan 27. doi: 10.18632/oncotarget.7028

Scientific Repprt. 2015; 5: 16106. Published online 2015 November 4. doi: 10.1038/srep16106

eLIFE. 2016 Feb 2; 5. pii: e08851. doi: 10.7554/eLife.08851.

Genome Biol. 2015 Dec 1; 16:259. doi: 10.1186/s13059-015-0831-x.

PLoS Genet. 2015 May 14; 11(5):e1005247. doi: 10.1371/journal.pgen.1005247.

Dev Cell. 2014 Feb 24; 28(4):366-80. doi: 10.1016/j.devcel.2014.01.016.

Biochem Biophys Res Commun. 2014 Jan 31; 444(1):86-91. doi: 10.1016/j.bbrc.2014.01.018.

PLoS Genet. 2013 Nov; 9(11):e1003791. doi: 10.1371/journal.pgen.1003791.

Methods. 2013 Sep 1; 63(1): 76-84. doi: 10.1016/j.ymeth.2013.05.001.

Bioinformatics. 2012 Dec 1; 28(23): 3147-9. doi: 10.1093/bioinformatics/bts587.

Bioinformatics. 2012 Nov 1; 28(21): 2843-4. doi: 10.1093/bioinformatics/bts521.

RNA Biol. 2011 May-Jun; 8(3): 538-47.

RNA. 2011 Mar; 17(3): 390-400. doi: 10.1261/rna.2426511.

Genetics. 2008 May; 179(1): 21-30. doi: 10.1534/genetics.107.086025.

Science. 2007 Oct 12; 318(5848):245-50.

Genomics. 2007 Apr; 89(4): 490-501. Epub 2007 Jan 11.

Mol Biol Evol. 2009 Feb;26(2):327-34. doi: 10.1093/molbev/msn249. Epub 2008 Nov 4

Wang Hailiang Vice President Co-founder

Graduated from Shandong University Pharmacy (formerly Shandong Medical College), MBA of Guanghua School of Management. More than 20 years of experience in marketing management in the pharmaceutical industry. He has worked in drug marketing in Beijing Hospital and Merck East China. He used to be the vice president of the giant Hong Kong listed company.